Mutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer

Oncology Letters

Volumn 10, Issue 3, 2015, Pages 1423-1429

  Stec, Rafał ^a   Semeniuk Wojtaś, Aleksandra ^a   Charkiewicz, Radosław ^b   Bodnar, Lubomir ^a   Korniluk, Jan ^a   Smoter, Marta ^a   Chyczewski, Lech ^b   Nikliński, Jacek ^b   Szczylik, Cezary ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Colorectal cancer; Phosphatidylinositol 4,5 bisphosphate 3 kinase catalytic subunit alpha mutations; Prognostic factor

Indexed keywords

B RAF KINASE; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; COLORECTAL CANCER; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PIK3CA GENE; POLYMERASE CHAIN REACTION; VERY ELDERLY;

EID: 84937404786     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3398     Document Type: Article

References (31)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, MathersC, Rebelo M, Parkin DM, Forman D and Bray F: GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr. Accessed April 30, 2014.
2. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH and Gabbert HE: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res16: 790-799, 2010.
3. Custodio A and Feliu J: Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations. Crit Rev Oncol Hematol85: 45-81, 2013.
4. Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, DingH, Mao C and Tang JL: Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A systematic review with meta-analysis. Int J Cancer133: 1914-1925, 2013.
5. Soeda H, Shimodaira H, Watanabe M, Suzuki T, Gamoh M, MoriT, Komine K, Iwama N, Kato S and Ishioka C: Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan-and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. Int J Clin Oncol18: 670-677, 2013.
6. German S, Aslam HM, Saleem S, Raees A, Anum T, Alvi AA and Haseeb A: Carcinogenesis of PIK3CA. Hered Cancer Clin Pract11: 5, 2013.
7. Zhu K, Yan H, Wang R, Zhu H, Meng X, Xu X, Dou X and ChenD: Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer. Med Oncol31: 16, 2014.
8. Stintzing S and Lenz HJ: A small cog in a big wheel: PIK3CA mutations in colorectal cancer. JNatl Cancer Inst105: 1775-1776, 2013.
9. Ikenoue T, Kanai F, Hikiba Y, etal: Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res65: 4562-4567, 2005.
10. Rosty C, Young JP, Walsh MD, etal: PIK3CA activating mutation in colorectal carcinoma: Associations with molecular features and survival. PLoS ONE8: e65479, 2013.
11. Shen Y, Wang J, Han X, Yang H, Wang S, Lin D and Shi Y: Effectors of epidermal growth factor receptor pathway: The genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoS ONE8: 12, 2013.
12. Soeda H, Shimodaira H, Watanabe M, Suzuki T, Gamo M, Takahashi M, Komine K, Kato S and Ishioka C: KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment. Mol Clin Oncol2: 356-362, 2014.
13. Huang L, Liu Z, Deng D, Tan A, Liao M, Mo Z and YangX: Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: A meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients. Arch Med Sci10: 1-9, 2014.
14. Eisenhauer EA, Therasse P, Bogaerts J, etal: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer45: 228-247, 2009.
15. Stec R, Bodnar L, Charkiewicz R, etal: K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan-or oxaliplatin-based chemotherapy. Cancer Biol Ther13: 1235-1243, 2012.
16. Samuels Y, Wang Z, Bardelli A, etal: High frequency of mutations of the PIK3CA gene in human cancers. Science304: 554, 2004.
17. Li VS, Wong CW, Chan TL, Chan AS, Zhao W, Chu KM, SoS, Chen X, Yuen ST and Leung SY: Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer5: 29, 2005.
18. De Roock W, Claes B, Bernasconi D, etal: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol11: 753-762, 2010.
19. Razis E, Pentheroudakis G, Rigakos G, etal: EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. JCancer Res Clin Oncol140: 737-748, 2014.
20. Tejpar S and Piessevaux H: Personalized medicine in metastatic colorectal cancer treated with anti-epidermal growth factor receptor agents: A future opportunity? Asia Pac J Clin Oncol10: 2-10, 2014.
21. Domagała P, Hybiak J, Sulżyc-Bielicka V, Cybulski C, Ryś J and Domagała W: KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: A practical approach. Pol J Pathol63: 145-164, 2012.
22. Ogino S, Nosho K, Kirkner GJ, etal: PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. JClin Oncol27: 1477-1484, 2009.
23. Herreros-Villanueva M, Gomez-Manero N, MuñizP, García-Girón C and Coma del Corral MJ: PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population. Mol Biol Rep38: 1347-1351, 2011.
24. CathomasG: PIK3CA in Colorectal Cancer. Front Oncol4: 35, 2014.
25. Pentheroudakis G, Kotoula V, De Roock W, etal: Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: Interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer13: 49, 2013.
26. Sartore-Bianchi A, Martini M, Molinari F, etal: PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res69: 1851-1857, 2009.
27. Prenen H, De Schutter J, Jacobs B, De Roock W, BiesmansB, Claes B, Lambrechts D, Van Cutsem E and Tejpar S: PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res15: 3184-3188, 2009.
28. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, LadelundS and Nilbert M: The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol53: 852-864, 2014.
29. Karapetis CS, Jonker D, Daneshmand M, etal; NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group: PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. Clin Cancer Res20: 744-753, 2014.
30. Ogino S, Liao X, Imamura Y, etal; Alliance for Clinical Trials in Oncology: Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. JNatl Cancer Inst105: 1789-1798, 2013.
31. Liao X, Morikawa T, Lochhead P, etal: Prognostic role of PIK3CA mutation in colorectal cancer: Cohort study and literature review. Clin Cancer Res18: 2257-2268, 2012.